IUPAC Name: N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
Molecular Formula: C₁₅H₁₉NO₂ 
Molecular Weight: 245.32 g/mol
Canonical SMILES: CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2
InChI: InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
Classification Code: Sleep disorders
XLogP3-AA: 2.2
H-Bond Donor: 1
H-Bond Acceptor: 2
Index of Refraction: 1.564 
Molar Refractivity: 69.664 cm³ 
Molar Volume: 214.079 cm³ 
Polarizability: 27.617×10^-24 cm³ 
Surface Tension: 47.161 dyne/cm 
Density: 1.146 g/cm³ 
Flash Point: 221.448 °C 
Enthalpy of Vaporization: 70.004 kJ/mol 
Boiling Point: 442.553 °C at 760 mmHg 
Vapour Pressure of Tasimelteon (CAS NO.609799-22-6): 0 mmHg at 25 °C

 Tasimelteon(CAS NO.609799-22-6) is a drug which is under development for the treatment of insomnia and other sleep disorders. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to older drugs such as ramelteon. It was shown to improve both onset and maintenance of sleep, with few side effects.

 Tasimelteon (CAS NO.609799-22-6), its Synonyms are N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide ; Propanamide, N-(((1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)- ; (1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide .